Claims:

1. An immunogenic composition comprising: (a) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:14 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:14; or

   (b) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:16 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:16.

2. The immunogenic composition of claim 1, further comprising: (c) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6.

3. The immunogenic composition of claim 1, comprising: (a) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:14, and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:14; (b) a nucleic acid molecule encoding one or more proteins selected from the group consisting of SEQ ID NO:16 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:16; and (c) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6.

4. The immunogenic composition of claim 3, wherein the nucleic acid molecules comprise one or more nucleotide sequences selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:13, and SEQ ID NO:15.

5. The immunogenic composition of claim 1, wherein the nucleic acid molecules are plasmids.

6. The immunogenic composition of claim 1, wherein the nucleic acid molecules are incorporated into viral particles.

7. The immunogenic composition of claim 1 further comprising an adjuvant molecule.

8. The immunogenic composition of claim 7, wherein the adjuvant is IL-12, IL-15, IL-28, or RANTES.

9. Use of an immunogenic composition of claim 1 in the manufacture of a medicament for inducing an immune response against an HBV antigen in a subject.

10. An immunogenic composition of claim 1 for use in the treatment of, or a subject who has been diagnosed with, HBV infection.

. .